# Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults

> **NCT06616922** · PHASE2 · COMPLETED · sponsor: **NTC srl** · enrollment: 252 (actual)

## Conditions studied

- Conjunctivitis, Bacterial

## Interventions

- **DRUG:** RD03/2016 eye drops
- **DRUG:** Levofloxacin 0.5% eye drops solution (Oftaquix®)

## Key facts

- **NCT ID:** NCT06616922
- **Lead sponsor:** NTC srl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-05
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-09-19
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06616922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06616922, "Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06616922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*